Accessibility statement

The Royal Pharmaceutical Society of Great Britain is committed to making its websites and mobile applications accessible, in accordance with the European Accessibility Act (EAA) (also known as Directive (EU) 2019/882).

This accessibility statement applies solely to The Pharmaceutical Journal website (www.pharmaceutical-journal.com).

We want as many people as possible to be able to use this website. For example, that means you should be able to:

How accessible this website is

We know some parts of this website are not currently fully accessible and we will be working to improve this over time. For example:

Compliance status

This website is partially compliant with Web Content Accessibility Guidelines version 2.2 AA standard (WCAG v2.2 AA), due to the non-compliances and exemptions listed below.

Non-accessible content

The content listed below is not accessible for the following reasons:

(a) Non-compliance with the accessibility legislation:

(b) Out of scope of the legislation:

Preparation of this accessibility statement

This statement was prepared on: 1 July 2025

Method used to prepare the statement: Self-assessment

Last reviewed on: 1 July 2025

Feedback and contact information

If you experience any accessibility barriers or need content in an alternative format, please contact us:

The Pharmaceutical Journal support team: pharmpress-support@rpharms.com

Enforcement procedure

If you are not satisfied with our response, you may file a complaint via the enforcement procedure: Equality and Human Rights Commission (EHRC)

Email: complaints@equalityhumanrights.com

Address

Correspondence Unit
Equality and Human Rights Commission
Arndale House
Arndale Centre
Manchester
M4 3AQ